Credence MedSystems Secures $39.9 Million Financing to Enable Scaling of Innovative Drug Delivery and Connected Health Systems
Credence MedSystems, Inc. announced today that it has closed a funding round with gross proceeds of $39.9 million. Sources of funding include strategic investments from Novartis Pharma AG, Molex Ventures LLC as well as additional investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005044/en/
The investment will be directed towards scaling of production capacity for the Credence Companion® and Dual Chamber Reconstitution Systems as well as development of other members of the Company’s platform of innovative drug delivery systems, including its connected health portfolio.
“The funding comes at a great time as we take the manufacturing of our Companion and Dual Chamber systems to the next level to meet pent-up demand in the market,” stated John Merhige, Credence’s Chief Commercial Officer. Jeff Tillack, Credence’s Chief Operating Officer, added, “Our immediate focus is on implementing the production capacity to support our customers’ needs, including GMP production for clinical use.”
Credence’s lead products are the Companion® Safety Syringe System and the Dual Chamber Reconstitution System, which provide critical usability and safety features to end-users along with operational efficiencies to pharma manufacturers. Additionally, the products enable pharma manufacturers to leverage sustainability advantages stemming from the reduced use of plastic and smaller footprint compared to conventional approaches.
Funding also supports acceleration of Credence’s connected health programs. The Credence Connect™ Auto-Sensing Injection System brings digital connectivity to any syringe, allowing critical information about the injection to be automatically captured and transmitted to a smart phone and the cloud. The Connect has the potential to impact chronic disease management and clinical trial compliance.
About Credence MedSystems, Inc.
Credence MedSystems is an innovator of drug delivery systems that solve unmet market needs for the pharmaceutical industry. Credence’s philosophy of Innovation Without Change allows pharma manufacturers to impress and protect their end users while preserving their existing processes, sourcing strategies and preferred primary package components. The Companion® family of syringe systems includes proprietary needle retraction technology, syringe reuse prevention and other critical safety and usability features. The Dual Chamber Reconstitution platform offers single-step mixing and injection for medicines that require reconstitution at the time of delivery. The Credence Connect™ brings digital connectivity to any syringe. Metered dose systems and other novel devices address the needs of specific therapeutic markets such as ocular therapies and cosmetic applications. Find more information on www.CredenceMed.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TX-SCHLUMBERGER-LIMITED22.10.2021 12:52:09 CEST | Press release
Schlumberger Announces Third-Quarter 2021 Results
DISRUPTIVE.ASIA22.10.2021 12:32:08 CEST | Press release
Disruptive.Asia: Huawei's Ryan Ding and Peng Song Discuss How Operators Can Leverage Connectivity to Unlock New Growth
SUZANO22.10.2021 12:21:06 CEST | Press release
Suzano Brings Its Target for Capturing 40 Million Tons of Carbon From the Atmosphere Forward To 2025
ANT-GROUP22.10.2021 12:03:04 CEST | Press release
AntChain Launches Its First Security Chip and New Blockchain Platform Powered by Privacy Computing Technology
TOTAL-TELECOM22.10.2021 12:02:04 CEST | Press release
Total Telecom: Maximizing the Value of Connectivity
EGLE-THERAPEUTICS22.10.2021 11:32:10 CEST | Press release
Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers
HFZA22.10.2021 10:02:13 CEST | Press release
HFZA inks investment deal with ArcelorMittal DSTC FZE
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom